Vera Therapeutics(VERA) GlobeNewswire News Room·2024-10-02 10:30Clinical Trial Updates - Long-term results from the ORIGIN Phase 2b clinical trial of atacicept for IgAN treatment will be presented at ASN Kidney Week 2024, alongside two informational posters detailing the ORIGIN Phase 3 and ORIGIN Extend trials [1] - The ORIGIN Phase 2b trial met its primary and key secondary endpoints, showing statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR compared to placebo through 36 weeks [6] - Atacicept demonstrated further reductions in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of eGFR through 72 weeks, reflecting a profile consistent with the general population without IgAN [6] Upcoming Events - An in-person and virtual R&D Day will be held in New York on October 2, 2024, featuring discussions on expanded atacicept R&D activities with key opinion leaders and the company's management team [3] - The ASN Kidney Week 2024 presentations include a late-breaking oral presentation on the ORIGIN Phase 2b study and two informational posters on the ORIGIN Phase 3 and ORIGIN Extend trials [1][2] Product and Pipeline Overview - Atacicept is a fusion protein that blocks BAFF and APRIL, targeting B cells and plasma cells to reduce autoantibodies in autoimmune diseases like IgAN and lupus nephritis [4][5] - The product has received FDA Breakthrough Therapy Designation for IgAN, reflecting its potential to demonstrate substantial improvement over available therapies [7] - Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize BK virus infection, particularly in kidney transplant settings [4] Company Background - Vera Therapeutics is a late clinical-stage biotechnology company focused on developing transformative treatments for serious immunological diseases [4] - The company retains global developmental and commercial rights to atacicept and MAU868 [4]